OSE Immunotherapeutics Reports 65% Overall Survival Rate in Phase 2 Cancer Vaccine Trial at ASCO 2025
OSE Immunotherapeutics presented positive Phase 2 results for Tedopi®, their neo-epitope-based therapeutic cancer vaccine, at ASCO 2025.
The TEDOPaM study demonstrated a 65% overall survival rate among advanced pancreatic cancer patients treated with Tedopi®, representing a significant milestone for this aggressive malignancy.
Tedopi® combines 10 neo-epitopes derived from five tumor antigens, targeting HLA-A2 positive patients, and is being evaluated in multiple cancer indications.